Our study explored the adverse prognostic effect of mutant TET2 on AML patients based on aspects of patients cohort, age, and risk stratification, which can bring great benefits to prognosis evaluation and therapy strategy guidance. The gene discussed is TET2; the disease is acute myeloid leukemia.